Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Nov

Today In Oncology

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Related Videos

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Study Finds Personalized Risk Messages Had No Effect in Raising Colorectal Cancer Screening Participation

My 50 Years in Lymphoma: Lessons Learned?

Does Kidney Stone History Impact Survival Outcomes in Upper Tract Urothelial Carcinoma

Active Surveillance With Metformin vs Placebo in Low-Risk Prostate Cancer

Izalontamab Brengitecan in Recurrent or Metastatic Nasopharyngeal Carcinoma